COLD SPRING HARBOR, N.Y.--(BUSINESS WIRE)--Cold Spring Harbor Laboratory (CSHL) today announced that Teri F. Willey has been appointed Vice President of Business Development and Technology Transfer. In this newly created position, Ms. Willey will direct the Laboratory's commercialization and technology transfer activities, including patenting, licensing, company start-ups, and corporate partnerships and collaborations.
Ms Willey joins CSHL from Mount Sinai Medical Center, where she successfully led the center's technology transfer and business development efforts. John Maroney, who previously had responsibility for technology transfer activities, will continue in his role as General Counsel.
Ranked #1 in the world for research impact in the fields of molecular biology and genetics, CSHL has a rich history of biomedical discovery and technology advancement and has sparked more than 20 start-up biotech companies -- including one of Long Island's biggest pharmaceutical success stories, cancer drug developer OSI Pharmaceuticals, which was recently acquired by Astellas.
"CSHL's transformative discoveries over many years in such areas as cancer, autism and other neuropsychiatric disorders, genome analysis, plant biology, and biofuels have significant commercial applications that will improve diagnostic and therapeutic approaches in the clinic as well as in agriculture and energy production," said CSHL President Bruce Stillman. "The appointment of Teri Willey to this new position will ensure that our research advances are applied to society's biggest challenges in healthcare, the environment, and world hunger and will enable us to maximize the economic potential of the biomedical research cluster on Long Island. Ms. Willey has an outstanding reputation and track record, and we are extremely pleased to welcome her to CSHL."
Ms. Willey has had a distinguished career in technology transfer and venture capital. Most recently, she served as Vice President of Technology & Business Development at Mount Sinai Medical Center in Manhattan. As the head of commercialization at Mount Sinai, she is credited with reorganizing technology transfer to support the medical center's vibrant innovation agenda through partnerships with industry, investors and funders.
Prior to joining Mount Sinai, Ms. Willey was founding Chief Executive and Executive Director, Cambridge Enterprise Ltd, The University of Cambridge, UK, and was a co-founder and Managing Partner of ARCH Development Partners, a seed venture fund and spin out from the University of Chicago and Argonne National Laboratory technologies. Earlier in her career, she served in technology transfer and business development at Purdue Research Foundation, Indiana Corporation for Science & Technology, and Northwestern University. She has served as an advisor to Congress and is a past President of the Association of University Technology Managers.
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for the impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.
Cold Spring Harbor Laboratory
Dagnia Zeidlickis, 516-367-8455